#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16436	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2137	765.2	0	.	n	.	0	C451T	SNP	451	451	C	719	719	T	928	T,C	877,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16436	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2137	765.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1452	1452	C	958	C	888	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29260	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3503	831.2	0	.	n	.	0	T695C	SNP	695	695	T	1010	1010	C	926	C,T	850,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29260	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3503	831.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2286	2286	C	962	C,A	892,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29260	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3503	831.2	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2912	2912	T	924	T,C	874,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	29260	23S	2890	2890	99.9	23S.l15.c17.ctg.1	3503	831.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2360	2360	A	896	A	842	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	2110	folP	855	855	100.0	folP.l15.c4.ctg.1	1474	142.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1025	1027	AGC	214;213;211	A;G;C,A	199;198;198,1	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5444	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3301	164.2	1	SNP	p	S91F	1	.	.	271	273	TTC	524	526	TTC	163;162;162	T;T;C	156;155;154	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5444	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3301	164.2	1	SNP	p	D95G	1	.	.	283	285	GGC	536	538	GGC	170;172;173	G;G,C;C	161;159,1;160	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5444	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3301	164.2	1	SNP	p	G95N	0	.	.	283	285	GGC	536	538	GGC	170;172;173	G;G,C;C	161;159,1;160	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	27	1728	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1455	118.1	1	SNP	p	G45D	0	.	.	133	135	GGC	544	546	GGC	208;211;210	G;G;C,T	197;197;198,1	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	868	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	971	88.6	0	.	n	.	0	A197.	DEL	197	197	A	563	563	A	200	A	189	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6108	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3084	197.5	1	SNP	p	D86N	0	.	.	256	258	GAC	601	603	GAC	255;256;257	G;A;C	233;234;235	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6108	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3084	197.5	1	SNP	p	S87R	1	.	.	259	261	CGT	604	606	CGT	254;254;256	C;G;T	233;232;231	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6108	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3084	197.5	1	SNP	p	R87W	0	.	.	259	261	CGT	604	606	CGT	254;254;256	C;G;T	233;232;231	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6108	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3084	197.5	1	SNP	p	R87I	0	.	.	259	261	CGT	604	606	CGT	254;254;256	C;G;T	233;232;231	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	6108	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3084	197.5	1	SNP	p	S88P	0	.	.	262	264	TCC	607	609	TCC	255;253;254	T;C;C	231;230;231	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4342	parE	1986	1986	100.0	parE.l15.c17.ctg.1	2430	177.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1442	1444	GGC	207;205;205	G;G;C,T	188;188;183,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	A311V	0	.	.	931	933	GCC	1177	1179	GCC	229;232;232	G;C;C	211;216;216	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	I312M	1	.	.	934	936	ATG	1180	1182	ATG	232;231;232	A,T;T;G	215,1;215;216	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	T316P	0	.	.	946	948	ACC	1192	1194	ACC	239;239;241	A;C;C	216;220;222	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	V316T	1	.	.	946	948	ACC	1192	1194	ACC	239;239;241	A;C;C	216;220;222	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1693	1695	ACC	220;221;224	A;C;C	197;203;205	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1747	1749	GCG	220;220;221	G;C,A;G	205;201,1;203	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1747	1749	GCG	220;220;221	G;C,A;G	205;201,1;203	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1870	1872	GGT	204;202;203	G;G;T	181;177;179	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1879	1881	AGC	189;187;189	A;G;C	170;167;169	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	4132	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2244	182.3	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1897	1899	CCG	158;163;164	C,G;C,G;G	122,3;130,1;132	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6338	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3207	197.1	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1658	1660	CCG	228;231;232	C;C;G	210;215;215	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2734	porA	1146	1146	99.91	porA.l6.c4.ctg.1	1754	154.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	562	562	C	201	C,G	180,1	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	A251V	NONSYN	751	753	GCG	68	70	GTA	39;39;39	G;T;A	35;35;34	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	S271T	NONSYN	811	813	TCG	128	130	ACT	48;46;45	A;C;T	44;42;40	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	134	136	GAT	38;36;34	G;A;T	33;31;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	D276N	NONSYN	826	828	GAT	143	145	AAC	33;33;33	A;A;C	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	N277H	NONSYN	829	831	AAC	146	148	CAC	33;33;32	C;A;C	30;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	R307E	NONSYN	919	921	AGA	236	238	GAA	12;12;12	G;A;A	12;12;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	248	250	GCA	13;13;13	G;C;A	12;12;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	251	253	GAC	14;14;14	G;A;C	14;12;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	257	259	ATC	14;14;13	A;T;C	14;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	263	265	TCG	14;14;13	T;C;G	14;14;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	269	271	GCC	14;15;15	G;C;C	14;15;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	272	274	AGC	15;15;15	A;G;C	13;13;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	275	277	GCC	15;15;15	G;C;C	14;15;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	292	porB1a	984	274	91.61	porB1a.l15.c17.ctg.1	371	25.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	281	283	GTT	15;15;15	G;T;T	14;14;14	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	0	.	p	.	0	I45V	NONSYN	133	135	ATT	403	405	GTT	236;235;233	G;T;T	225;219;221	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	0	.	p	.	0	G50D	NONSYN	148	150	GGC	418	420	GAC	240;240;240	G;A,G;C	223;221,3;224	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	0	.	p	.	0	E52K	NONSYN	154	156	GAA	424	426	AAA	238;235;237	A,G;A;A	220,3;221;221	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	0	.	p	.	0	G256D	NONSYN	766	768	GGT	1036	1038	GAT	269;265;265	G;A,G;T	250;246,1;247	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	1	SNP	p	G120K	1	.	.	358	360	AAG	628	630	AAG	258;256;259	A;A;G,C	239;239;233,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	1	SNP	p	A121N	1	.	.	361	363	AAC	631	633	AAC	258;260;257	A;A,G;C	237;239,1;236	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	3222	porB1b	1038	1038	99.61	porB1b.l6.c4.ctg.1	1506	211.9	1	SNP	p	N121D	0	.	.	361	363	AAC	631	633	AAC	258;260;257	A;A,G;C	237;239,1;236	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11532	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4872	235.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1326	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1230	107.7	1	SNP	p	V57M	1	.	.	169	171	ATG	556	558	ATG	296;296;295	A;T;G	274;276;275	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
